Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Takeda offloads URL generics business to Caraco for $65m

This article was originally published in Scrip

Executive Summary

In a move expected since it completed the acquisition of the private US firm in June, Takeda is divesting the generics business of URL Pharma, with the Caraco Pharmaceutical Laboratories subsidiary of India's Sun Pharmaceutical Industries emerging as the buyer.

You may also be interested in...



Newron Not Seeing Sarizotan STARS Yet

The Italian firm has some talking to do with the US FDA before it can unblind Phase III data on sarizotan, its Rett syndrome therapy which could be "potentially transformative" for Newron.

Warning Letter Roundup & Recap – 10 December 2019

No device-related warning letters were released by the US FDA the week of 10 December.

Immuno-Oncology Continues To Draw Pharma Companies To The Deal Table

Immuno-oncology development trends are revealed through an analysis of deals between cancer drug developers over the past five years.

Topics

Related Companies

UsernamePublicRestriction

Register

SC019794

Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel